Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.1%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)’s stock price traded down 7.1% on Wednesday . The stock traded as low as $11.63 and last traded at $11.68. 445,154 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 791,847 shares. The stock had previously closed at $12.57.

Analysts Set New Price Targets

A number of analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Wedbush boosted their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $38.57.

Zentalis Pharmaceuticals Trading Down 6.4 %

The stock has a market capitalization of $835.20 million, a PE ratio of -2.61 and a beta of 1.73. The stock’s fifty day simple moving average is $14.16 and its 200-day simple moving average is $13.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.09. As a group, analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the sale, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at $5,164,576.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC increased its position in shares of Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after buying an additional 3,745,936 shares during the period. Vanguard Group Inc. increased its position in shares of Zentalis Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after buying an additional 307,490 shares during the period. Federated Hermes Inc. increased its position in shares of Zentalis Pharmaceuticals by 10.9% during the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after buying an additional 212,872 shares during the period. Decheng Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $31,809,000. Finally, Wellington Management Group LLP increased its position in shares of Zentalis Pharmaceuticals by 0.5% in the third quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company’s stock worth $38,457,000 after purchasing an additional 8,661 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.